IPA Leadership

Since 2019 Dirk Witters is an independent advisor and executive partner in a family office structure, where he advises on capital raising assignments (cumulative volume of EUR 250 million raised through the family office network) and direct investments in industries including healthcare and real estate development.  In this capacity Dirk serves as director in an early-stage business in orthopedic implants  and in an HR-services provider.

From mid 2020 to April 2022, Dirk was President of the Board of Biostrand BV (discontinued when the company was acquired by IPA).

Previously Mr. Witters served as executive partner in a corporate finance boutique and was advisor to the founder of New Rhein Healthcare Investors, a private equity investment firm focused on healthcare therapeutics and medical devices, where he assisted with the capital raise of the second investment fund.

Mr. Witters also spent 20+ years with KBC Group’s Corporate and Investment Banking division where he gained experience in business development, strategy execution, advisory and corporate finance.

Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global client relations and high value target teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Dr. Kamil Isaev is a technology leader and venture strategist with over 30 years of experience in AI, semiconductor technologies, and global R&D operations. He specializes in bridging innovation with commercialization, driving the adoption of AI-driven solutions across biotechnology, healthcare, and enterprise computing.

Currently a Venture Partner at ABRT VC, Kamil leads the ABRT AI Lab and the VC Score project, using AI to evaluate startups and guide investment decisions. Previously, he held key leadership roles at Intel Corporation, where he focused on AI computing optimization, GPU workload migration, and enterprise AI deployment.

Kamil has also led R&D and commercialization efforts at Align Technology, Caresyntax, and Dell EMC, scaling AI-driven solutions in healthcare, cloud computing, and digital transformation. An IEEE member, guest lecturer, and industry speaker, he holds an MSc and PhD in Physics from Moscow State University and has authored over 30 scientific publications.

At ImmunoPrecise Antibodies, Kamil applies his expertise in AI and strategic innovation to advance AI-driven biologics discovery and commercialization.